Atlas Trials

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Clinical trial NCT03150329 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03150329
Sponsor
City of Hope Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Grade 3b Follicular LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRecurrent Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRefractory Classic Hodgkin Lymphoma
Start date
2017-07-18
Primary completion
2023-06-23
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.